These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 19097942)

  • 1. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.
    Hacke W; Furlan AJ; Al-Rawi Y; Davalos A; Fiebach JB; Gruber F; Kaste M; Lipka LJ; Pedraza S; Ringleb PA; Rowley HA; Schneider D; Schwamm LH; Leal JS; Söhngen M; Teal PA; Wilhelm-Ogunbiyi K; Wintermark M; Warach S
    Lancet Neurol; 2009 Feb; 8(2):141-50. PubMed ID: 19097942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
    Hacke W; Albers G; Al-Rawi Y; Bogousslavsky J; Davalos A; Eliasziw M; Fischer M; Furlan A; Kaste M; Lees KR; Soehngen M; Warach S;
    Stroke; 2005 Jan; 36(1):66-73. PubMed ID: 15569863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
    Albers GW; von Kummer R; Truelsen T; Jensen JK; Ravn GM; Grønning BA; Chabriat H; Chang KC; Davalos AE; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A;
    Lancet Neurol; 2015 Jun; 14(6):575-84. PubMed ID: 25937443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.
    Furlan AJ; Eyding D; Albers GW; Al-Rawi Y; Lees KR; Rowley HA; Sachara C; Soehngen M; Warach S; Hacke W;
    Stroke; 2006 May; 37(5):1227-31. PubMed ID: 16574922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refinement of the magnetic resonance diffusion-perfusion mismatch concept for thrombolytic patient selection: insights from the desmoteplase in acute stroke trials.
    Warach S; Al-Rawi Y; Furlan AJ; Fiebach JB; Wintermark M; Lindstén A; Smyej J; Bharucha DB; Pedraza S; Rowley HA
    Stroke; 2012 Sep; 43(9):2313-8. PubMed ID: 22738918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desmoteplase.
    Paciaroni M; Medeiros E; Bogousslavsky J
    Expert Opin Biol Ther; 2009 Jun; 9(6):773-8. PubMed ID: 19456211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke).
    von Kummer R; Mori E; Truelsen T; Jensen JS; Grønning BA; Fiebach JB; Lovblad KO; Pedraza S; Romero JM; Chabriat H; Chang KC; Dávalos A; Ford GA; Grotta J; Kaste M; Schwamm LH; Shuaib A; Albers GW;
    Stroke; 2016 Dec; 47(12):2880-2887. PubMed ID: 27803391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke.
    Mori E; Minematsu K; Nakagawara J; Hasegawa Y; Nagahiro S; Okada Y; Truelsen T; Lindsten A; Ogawa A; Yamaguchi T;
    Stroke; 2015 Sep; 46(9):2549-54. PubMed ID: 26251244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program.
    von Kummer R; Albers GW; Mori E;
    Int J Stroke; 2012 Oct; 7(7):589-96. PubMed ID: 22989394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
    Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
    Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
    Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW
    Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase.
    Fiebach JB; Al-Rawi Y; Wintermark M; Furlan AJ; Rowley HA; Lindstén A; Smyej J; Eng P; Warach S; Pedraza S
    Stroke; 2012 Jun; 43(6):1561-6. PubMed ID: 22474060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.
    Elkins J; Veltkamp R; Montaner J; Johnston SC; Singhal AB; Becker K; Lansberg MG; Tang W; Chang I; Muralidharan K; Gheuens S; Mehta L; Elkind MSV
    Lancet Neurol; 2017 Mar; 16(3):217-226. PubMed ID: 28229893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
    Campbell BCV; Ma H; Ringleb PA; Parsons MW; Churilov L; Bendszus M; Levi CR; Hsu C; Kleinig TJ; Fatar M; Leys D; Molina C; Wijeratne T; Curtze S; Dewey HM; Barber PA; Butcher KS; De Silva DA; Bladin CF; Yassi N; Pfaff JAR; Sharma G; Bivard A; Desmond PM; Schwab S; Schellinger PD; Yan B; Mitchell PJ; Serena J; Toni D; Thijs V; Hacke W; Davis SM; Donnan GA;
    Lancet; 2019 Jul; 394(10193):139-147. PubMed ID: 31128925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of GABA
    Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
    Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.
    Schellinger PD; Jansen O; Fiebach JB; Heiland S; Steiner T; Schwab S; Pohlers O; Ryssel H; Sartor K; Hacke W
    Stroke; 2000 Jun; 31(6):1318-28. PubMed ID: 10835451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischaemic stroke.
    Nakashima T; Toyoda K; Koga M; Matsuoka H; Nagatsuka K; Takada T; Naritomi H; Minematsu K
    Int J Stroke; 2009 Dec; 4(6):425-31. PubMed ID: 19930051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis.
    Li X; Ling L; Li C; Ma Q
    Medicine (Baltimore); 2017 May; 96(18):e6667. PubMed ID: 28471961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke--MRI-based decision making].
    Kakuda W; Abo M
    Brain Nerve; 2008 Oct; 60(10):1173-80. PubMed ID: 18975605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.
    Davis SM; Donnan GA; Parsons MW; Levi C; Butcher KS; Peeters A; Barber PA; Bladin C; De Silva DA; Byrnes G; Chalk JB; Fink JN; Kimber TE; Schultz D; Hand PJ; Frayne J; Hankey G; Muir K; Gerraty R; Tress BM; Desmond PM;
    Lancet Neurol; 2008 Apr; 7(4):299-309. PubMed ID: 18296121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.